Skip Navigation


Rheumatology Advance Access originally published online on March 29, 2005
Rheumatology 2005 44(5):573-576; doi:10.1093/rheumatology/keh609
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/5/573    most recent
keh609v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Watts, R.
Right arrow Articles by Williams, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watts, R.
Right arrow Articles by Williams, J.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

EDITORIAL

Translational research in autoimmunity: aims of therapy in vasculitis

Aims of Therapy/Series Editor: Lorraine Harper

R. Watts, L. Harper3, D. Jayne4, J. Levy2, C. Pusey2, C. Savage3, D. G. I. Scott1 and J. Williams3

Department of Rheumatology, Ipswich Hospital NHS Trust and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, 1 Department of Rheumatology, Norfolk and Norwich University Hospital NHS Trust and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, 2 Renal Section, Imperial College London, Hammersmith Hospitals NHS Trust, London, 3 Division of Immunity and Infection, Medical School, University of Birmingham, Birmingham and 4 Renal Medicine, Addenbrooke's Hospital, Cambridge, UK

Correspondence to: R. Watts, Department of Rheumatology, Ipswich Hospital NHS Trust, Heath Road, Ipswich IP4 5PD, UK. E-mail: Richard.watts@ipswichhospital.nhs.uk

The first 150 words of the full text of this article appear below.

Despite significant advances in treatment, the systemic vasculitides remain something of an enigma as the aetiology remains obscure. Five years ago a meeting ‘Vasculitis—Aims of Therapy’ was held in Cambridge to discuss the then state of the art in the management of vasculitis [1]. Since then there have been major advances in their treatment with the completion of the first wave of European Vasculitis Study Group (EUVAS) series of trials (NORAM, CYCAZREM and MEPEX) (see Table 1 for a summary). The results of these trials now provide a firm evidence base for the first line treatment of most patients presenting with systemic vasculitis. A major triumph has been the transformation of these diseases from conditions with an appalling prognosis to chronic relapsing and remitting diseases [2, 3].


View this table:
[in this window]
[in a new window]
  		TABLE 1. EUVAS trials in systemic vasculitis

 
In the first wave of EUVAS studies, The NORAM trial compared methotrexate (MTX) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?